Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued on Sunday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Shares of NASDAQ ONVO opened at $0.36 on Friday. Organovo has a 1 year low of $0.32 and a 1 year high of $1.74. The stock has a market capitalization of $5.52 million, a P/E ratio of -0.34 and a beta of 0.53. The company’s 50-day moving average is $0.41 and its 200 day moving average is $0.53.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Organovo stock. Armistice Capital LLC acquired a new stake in shares of Organovo Holdings, Inc. (NASDAQ:ONVO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 929,000 shares of the medical research company’s stock, valued at approximately $708,000. Armistice Capital LLC owned 6.46% of Organovo at the end of the most recent quarter. 8.23% of the stock is currently owned by institutional investors.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.